Patients with symptomatic multiple myeloma (MM) following induction and conditioning therapy and autologous stem cell transplant (ASCT) may derive survival benefit from maintenance therapy with ixazomib, according to the phase III TOURMALINE-MM3* trial.
The addition of daratumumab to lenalidomide and dexamethasone improved progression-free survival (PFS) in patients newly diagnosed with multiple myeloma (MM) who were ineligible for a stem cell transplant, according to interim results of the phase III multinational MAIA* trial.
Use of a single course of the intravenous iron preparation ferumoxytol may lead to sustained improvements in patient-reported outcomes (PROs) of individuals with iron deficiency anaemia (IDA) who had inadequate response to oral iron therapy, according to data presented at ASH 2018.
Lenalidomide, given for 14 days in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), has demonstrated acceptable toxicity in the REVAIL study in elderly patients with angioimmunoblastic T-cell lymphoma (AITL), with efficacy results similar to reports from previous studies.
Bortezomib in combination with thalidomide plus dexamethasone (VTD) significantly improves progression-free survival (PFS) and overall survival (OS) vs thalidomide plus dexamethasone (TD) alone in patients with newly diagnosed multiple myeloma (MM) undergoing double autologous stem cell transplantation (ASCT), 10-year results of the GIMEMA-MMY-3006 trial have shown.
Individuals with myeloma who relapse within a year (ie, progression-free survival [PFS] <12 months) after receiving autologous stem cell transplant (ASCT) may have high-risk disease, suggesting poor survival rates, according to the results of the MYELOMA XI* trial presented at ASH 2018.
A standardized strategy that excludes heparin bridging and pre-operative coagulation testing may be feasible and suitable for individuals with atrial fibrillation (AF) who require interruption of their direct oral anticoagulants (DOACs) prior to elective surgery, results of the PAUSE* study show.
Low rates of cardiovascular (CV) or major bleeding complications were observed among octogenarians who were receiving active NOAC* therapy, suggesting that long-term anticoagulation with NOACs may result in a good risk-benefit ratio in this patient subgroup, according to data presented at ASH 2018.
Luspatercept significantly reduces the need for blood transfusion in patients with β-thalassaemia, thus providing a new hope for patients with β-thalassaemia in whom no approved definitive curative treatments have been available yet other than bone marrow transplantation, according to the BELIEVE* study presented at ASH 2018.